文献速递前列腺癌

SpaceOAR水凝胶间隔物减少前列腺癌放疗毒性的系统综述

SpaceOAR Hydrogel Spacer for Reducing Radiation Toxicity During Radiotherapy for Prostate Cancer. A Systematic Review.
PubMed 文献 · Urology · 2021-05-23

该系统综述纳入19项研究共3622例患者,评估SpaceOAR水凝胶间隔物与前列腺癌各放疗方式下直肠剂量、毒性和生活质量的关联。仅1项为IG-IMRT的随机对照试验,其余为非随机对照研究。结果显示SpaceOAR显著降低直肠辐射剂量及胃肠和泌尿生殖毒性,并改善多数生活质量域。

要点

  • SpaceOAR可显著降低直肠辐射剂量,如IG-IMRT中V40平均差异-9.1%。
  • SpaceOAR降低晚期胃肠和泌尿生殖毒性,如SBRT中晚期胃肠毒性1% vs 6%。
  • 多数生活质量域改善,如低剂量率近距离放疗联合EBRT中肠功能评分变化。

核心结论

  • IG-IMRT的随机对照试验表明SpaceOAR降低直肠辐射剂量及晚期胃肠和泌尿生殖毒性,并改善泌尿、肠道和性生活质量。
  • 观察性研究在不同放疗类型中验证了这些优势。
  • 需要进一步研究在超分割放疗中的作用。

研究设计与样本

  • 系统检索Cochrane Central Register of Controlled Trials、MEDLINE和Embase从建库至2020年5月。
  • 纳入19项研究共3622例患者,仅1项为IG-IMRT的随机对照试验,18项为EBRT、近距离放疗及其联合的非随机对照试验。
  • 未发现超分割研究。
  • 两名评价者独立筛选文献,数据提取和质量评估由一人完成、另一人核对,必要时由第三人裁决。
  • 采用叙述性综合。

主要发现

  • 无论放疗类型,SpaceOAR显著降低直肠辐射剂量,例如V40平均差异在高剂量率近距离放疗联合IG-IMRT中为-6.1%,在IG-IMRT中为-9.1%。
  • SpaceOAR降低胃肠和泌尿生殖毒性,例如立体定向体部放疗中晚期胃肠毒性1% vs 6%(P=.01),晚期泌尿生殖毒性15% vs 32%(P<.001)。
  • 多数Expanded Prostate Cancer Index Composite生活质量域改善,例如低剂量率近距离放疗联合EBRT中肠功能评分在3和6个月平均变化分别为0 vs -6.25和-3.57。

临床怎么用

  • 在前列腺癌放疗中可考虑使用SpaceOAR以减少直肠辐射剂量和晚期胃肠及泌尿生殖毒性。
  • 使用SpaceOAR可能改善患者泌尿、肠道和性生活质量。
  • 证据主要来自IG-IMRT的随机对照试验和各放疗类型的观察性研究,超分割放疗暂缺乏证据。

局限性

  • 仅1项随机对照试验,其余18项为非随机对照研究。
  • 未纳入超分割放疗研究。
  • 证据综合为叙述性,未进行定量合并。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the association between SpaceOAR and radiation dosing, toxicity and quality-of-life vs no spacer across all radiotherapy modalities for prostate cancer. METHODS: A systematic search of the Cochrane Central Register of Controlled Trials, MEDLINE, and Embase was performed from database inception through May 2020. Two reviewers independently screened titles/abstracts and full papers. Data extraction was performed, and quality assessed by 1 reviewer and checked by a second, using a third reviewer as required. The synthesis was narrative. RESULTS: 19 studies (3,622 patients) were included (only 1 randomized controlled trial, in image-guided intensity-modulated radiotherapy (IG-IMRT), 18 comparatives non-randomized controlled trials in external-beam radiotherapy (EBRT), brachytherapy, and combinations thereof). No hypofractionation studies were found. Regardless of radiotherapy type, SpaceOAR significantly reduced rectal radiation dose (eg, V40 average difference -6.1% in high dose-rate brachytherapy plus IG-IMRT to -9.1% in IG-IMRT) and reduced gastrointestinal and genitourinary toxicities (eg, late gastrointestinal toxicity 1% vs 6% (P = .01), late genitourinary toxicity of 15% vs 32% (P < .001) in stereotactic body radiotherapy). Improvements were observed in most Expanded Prostate Cancer Index Composite quality-of-life domains (eg, bowel function score decrease at 3 and 6 months: Average change of zero vs -6.25 and -3.57 respectively in low dose-rate brachytherapy plus EBRT). CONCLUSION: The randomized controlled trial in IG-IMRT demonstrated that SpaceOAR reduces rectal radiation dose and late gastrointestinal and genitourinary toxicities, with urinary, bowel, and sexual quality-of-life improvement. These advantages were verified in observational studies in various radiotherapy types. Further research is required in hypofractionation.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Armstrong N, Bahl A, Pinkawa M, et al. SpaceOAR Hydrogel Spacer for Reducing Radiation Toxicity During Radiotherapy for Prostate Cancer. A Systematic Review. Urology. 2021. PMID: 34029607. doi:10.1016/j.urology.2021.05.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。